Screener
Neuropace, Inc. NPCE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:33 PM EDT
- Fiscal quarter
- Q4 FY2030
- Calendar quarter
- Q4 2030
- Accession
- 0001528287-26-000030
| (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued liabilities | (2,489) | (120) |
| Deferred revenue | (18) | 141 |
| Operating lease liabilities | (1,036) | (911) |
| Net cash used in operating activities | (9,803) | (9,568) |
| Cash flows from investing activities | ||
| Acquisition of property and equipment | (242) | (205) |
| Net cash used in investing activities | (242) | (205) |
| Cash flows from financing activities |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Neuropace, Inc.'s operating cash flow?
- Neuropace, Inc. (NPCE) reported operating cash flow of -$3.9M in Q2 2026.
- How has Neuropace, Inc.'s operating cash flow changed year-over-year?
- Neuropace, Inc.'s operating cash flow decreased by 87.1% year-over-year, from -$2.09M to -$3.9M.
- What is the long-term trend for Neuropace, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Neuropace, Inc.'s operating cash flow has grown at a -17.3% compound annual growth rate (CAGR), from -$24.58M to -$11.51M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Neuropace, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude